One of the problems with all psychotropic drugs is that they have multiple actions. We heard today much about the dopamine system, but remember that chlorpromazine blocks dopamine receptors, acetylcholine receptors, a-adrenoceptors and 5HT receptors, among others. Consequently, it may be a complicated pattern of effects which is most clinically relevant.
Nevertheless, some of the actions, like dopamine blockade producing a rise in prolactin, may be of clinical utility. More widespread use of prolactin estimations in patients who are apparently taking their drugs but do not seem to be responding is justified. If the prolactin is high, then at least one knows that there is dopamine blockade in one part of the brain.
In discussion, Dr Iversen defended the biochemical theories of schizophrenia by saying that these drugs may act on as yet undetermined systems and that the biological substrate of schizophrenia may reside in as yet undiscovered systems. Certainly the changes that have occurred in the last 2-3 years in our knowledge of transmitters in the central nervous system are quite breathtaking. However, that the mechanism may not be dopamine over-activity but a supersensitivity of the receptors, is an intriguing possibility raised by Dr Crow, which generates testable hypotheses. On the other hand, I think that there are 2 problems. The first is that the data so far have not been obtained from many 'drug free' patients and it is very difficult to be sure that a patient is 'drug free'. Also, I cannot think of any medical condition which has been attributed to over-activity of receptors, except for tardive dyskinesia.
We had an interesting paper this morning from Dr Cookson who drew the psychoanalytic parallels to psychopharmacology. Freud regarded psychoanalysis as a stop-gap theory until we knew more about the brain and then neuropharmacology would come into its own, but somehow I doubt if the Id really resides in the nucleus accumbens. (It might be in the amygdala, though).
One interesting point which kept recurring was the relationship of mania and depression to schizophrenia. Mania, I think, is a neglected condition, despite having the least problems of ascertainment and of assessment of change. Pimozide, like other anti-psychotic agents, has an anti-manic action. We also know the importance in schizophrenic relapse of depressive changes. Indeed, in maintenance studies, much of the morbidity necessitating hospital readmission is depression and not a recrudescence of the schizophrenic phenomena. How close is the relationship between mania, depression and schizophrenia? Where do the schizoaffective psychoses fit in here and are they a separate entity ? We also discussed the problems of irregular drug taking. Dr Watt's paper suggested how problems and even biases enter into the selection of patient populations. Clinicians, in tendering patients for trials, take into account not only the prognosis (in terms of whether they are likely to relapse) but how much this is concerned with whether they are going to take any treatment, oral or injectable. In the last paper we heard of the problems of in-patient studies and how there is an ageing population in hospital becoming, I suspect, increasingly more untypical.
Pimozide seems effiective in specific syndroms, in MHP and in patients with apathetic and withdrawn symptomatology, but we do not know whether these actions are shared by other antipsychotic agents. But that does not affect our clinical management of the patients involving here-and-now decisions. We cannot wait for 10 years for the next trial to be published. 
